控股子公司内部控制制度 （2025年10月） 第一章 总 则 华邦生命健康股份有限公司 第一条 为加强华邦生命健康股份有限公司（以下简称"公司"） 对控股子公司的管理，确保控股子公司规范、高效、有序运作，切实 保护公司及投资者利益，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司治理准则》、《深圳证券交易所股票 上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等法律、法规、部门规章和《华邦生命健康股 份有限公司章程》（以下简称"《公司章程》"）的规定，制定本制 度。 第二条 本制度适用于公司总部及各级控股子公司。 第二章 规范运作 第八条 控股子公司应当依据《公司法》及有关法律法规的规定， 参照本制度的要求，建立起健全的法人治理结构和内部控制制度。 第九条 控股子公司应明确经营战略和经营方向，围绕主业审慎运 营，控股子公司董事、监事、高级管理人员应忠实履行对控股子公司 和公司的勤勉尽责义务。 第四条 本制度所称控股子公司是指根据公司总体战略规划或业 务发展需要而依法设立或收购的由公司控股或实际控制的具有独立法 人资格的有限责任公司或股份公司。 第五条 ...

证券代码：002004 证券简称：华邦健康 公告编号：2025048 华邦生命健康股份有限公司 关于控股股东的一致行动人部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司控股股东 的一致行动人张一卓先生的通知，获悉其将所持有本公司的部分股份办理质押业 务,具体情况如下： 一、本次质押基本情况 | 股东 | 是否为控股股东 | 本次质押股份 | 占其所持股 | 占公司总 | 是否 | 是否为 | | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 或第一大股东及 | 数量（股） | 份比例 | 股本比例 | 为限 | 补充质 | 质押起始日 | 解除质押日期 | 质权人 | 用途 | | | 其一致行动人 | | | | 售股 | 押 | | | | | | 张一卓 | 是 | 22,080,000 | 40.10% | 1.12% | 否 | 否 | 2025.10. ...

Core Viewpoint - Huabang Health has maintained a high dividend policy, distributing approximately 3 billion yuan in dividends since 2018, supported by its diversified business layout and high-profit advantages in the health industry [1][2][3] Dividend Policy and Shareholder Returns - The company has a strong foundation for maintaining high dividends and is considering sustainable profit distribution policies, including exploring diversified dividend methods [2] - A cash dividend plan of "10 for 2 yuan" has been proposed for 2025, with a total cash dividend amounting to 395 million yuan, representing 100% of the profit distribution total [2] - Despite the attractive dividend, the company faced challenges in 2024 due to goodwill impairment, leading to a suspension of cash dividends [2][3] Financial Health and Debt Pressure - As of mid-2025, Huabang Health's debt ratio was 46.17%, with a current ratio of 1.23, indicating some debt pressure [3] - The company had total current liabilities of approximately 9.38 billion yuan, including short-term loans of 3.27 billion yuan and non-current liabilities due within one year of 1.91 billion yuan, while cash and cash equivalents stood at only 2.946 billion yuan [3] - The significant short-term debt and insufficient cash reserves to cover these obligations present a challenge for the company [3] Business Diversification and Performance - Established in 1992 and listed in 2004, Huabang Health has developed a diversified business model focusing on the health industry, covering pharmaceuticals, medical services, agrochemicals, new materials, and tourism [4] - For the first half of 2025, the company reported a revenue of 5.945 billion yuan, a year-on-year increase of 0.39%, with operating profit of 667 million yuan, up 18.55%, and net profit attributable to shareholders of 388 million yuan, up 23.90% [4] - Despite overall growth, significant disparities exist among different business segments, particularly between the pharmaceutical sector and the agrochemical/new materials sector [5][6] Segment Performance - The pharmaceutical segment, as the core strength, achieved a revenue of 1.625 billion yuan with a gross margin of 78.59%, reflecting a 2.68% increase year-on-year [6] - In contrast, the agrochemical/new materials segment contributed 3.378 billion yuan in revenue, accounting for 56.82% of total revenue, but faced high costs leading to a low gross margin of 14.08% [6] - The company faces challenges in the agrochemical market due to intensified competition and declining prices, which negatively impact operations [6]

Core Viewpoint - Huabang Health's stock price has shown fluctuations, with a recent decline of 2.17% and a year-to-date increase of 15.02%, indicating mixed investor sentiment and market performance [1][2]. Financial Performance - For the first half of 2025, Huabang Health reported a revenue of 5.945 billion yuan, reflecting a year-on-year growth of 0.39%, while the net profit attributable to shareholders reached 388 million yuan, marking a significant increase of 23.90% [2]. - Cumulatively, the company has distributed 4.909 billion yuan in dividends since its A-share listing, with 1.265 billion yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 3.86% to 73,800, while the average circulating shares per person increased by 3.99% to 25,486 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.599 million shares to 21.982 million shares, and Invesco Great Wall CSI Dividend Low Volatility 100 ETF, which reduced its holdings by 550,200 shares to 15.6347 million shares [3]. Market Activity - The stock experienced a trading volume of 119 million yuan with a turnover rate of 1.26%, and the main funds saw a net outflow of 13.1342 million yuan, indicating a cautious market sentiment [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of -13.4632 million yuan on January 20, 2025 [1].

Core Insights - Huabang Health's stock increased by 5.09% to 5.16 CNY per share, with a trading volume of 365 million CNY and a turnover rate of 3.83%, resulting in a total market capitalization of 10.216 billion CNY [1] Company Overview - Huabang Life Health Co., Ltd. is located at 69 Xingguang Avenue, Renhe, Yubei District, Chongqing, established on March 11, 1992, and listed on June 25, 2004 [1] - The company's main business includes the research, production, and sales of pharmaceutical formulations, raw materials, and pesticides, as well as pharmaceutical distribution and pesticide import/export [1] - Revenue composition: Agricultural new materials 56.82%, pharmaceutical products 27.33%, tourism services 8.29%, others 4.34%, medical services 3.21% [1] Fund Holdings - Huabang Health is a significant holding in Huabao Fund, specifically in the Huabao Quantitative Stock Mixed Initiation A (017715), which held 104,600 shares in the second quarter, accounting for 1.37% of the fund's net value, ranking as the third-largest holding [2] - The fund has achieved a year-to-date return of 28.1%, ranking 3076 out of 8160 in its category, and a one-year return of 30.62%, ranking 2391 out of 8026 [2] Fund Manager Performance - The fund manager Xu Linming has a tenure of 16 years and 28 days, with a total fund asset size of 1.618 billion CNY, achieving a best return of 98.6% and a worst return of -43.03% during his tenure [3] - Co-manager Yu Yinyou has a tenure of 3 years and 111 days, managing assets of 491 million CNY, with a best return of 33.86% and a worst return of -0.92% [3]

Core Viewpoint - The company, Huabang Health, reported steady development in its pharmaceutical business, focusing on the research, production, and sales of pharmaceutical preparations and raw materials [1] Group 1: Business Development - The company is expanding its product categories while solidifying its existing offerings in skin treatment, anti-infection, and anti-tumor medications [1] - New growth points are being sought by expanding into cardiovascular, hypertension, and analgesic anti-inflammatory fields [1] Group 2: Product Line Expansion - The company is extending its focus from "skin treatment" to "skin care," actively launching a range of health products for skin [1] - Current product offerings include facial cleansers, whitening and spot-reducing products, soothing and repairing items, acne control, and baby skincare, all backed by pharmaceutical production management experience [1]

Core Viewpoint - The announcement from Huabang Health indicates that while the national collection of generic drugs is a trend aimed at controlling medical insurance costs and improving drug quality, its current impact on the company is relatively limited [1] Summary by Relevant Categories Impact of Generic Drug Collection - The progress of including topical drugs in the collection is slower compared to other medications, providing the company with a time window for further layout and adjustments [1] - The company is actively promoting the consistency evaluation of generic drugs while continuously controlling production costs and improving production processes, laying a solid foundation for participation in the collection [1] Product and Market Strategy - The company has a comprehensive pipeline in the dermatology field with numerous products, forming a product matrix targeting various diseases. After drugs are included in the collection, the company can mitigate impacts by promoting alternative drugs [1] - The company is not solely focused on chemical generics but has established a full industry chain around "big skin," including raw materials, formulations, functional skincare products, pan-skin health management, and medical services. Generic drugs are just one part of the business [1] Market Development and Innovation - The collection primarily targets the prescription market, and the company is leveraging the current time window to vigorously develop the broad market, enhancing terminal coverage through brand chain pharmacies and e-commerce channels to increase retail market share [1] - In addition to existing drugs, the company is actively advancing new drug research and development, rolling out 3-5 new projects annually to ensure a continuous stream of new products [1]

Core Viewpoint - The company emphasizes its commitment to shareholder returns through a consistent high dividend policy, having distributed approximately 3 billion yuan in dividends since 2018 [1] Group 1 - The company has maintained a high dividend payout ratio for several consecutive years [1] - Cumulative dividends paid by the company from 2018 to present amount to around 3 billion yuan [1] - The company plans to actively consider sustainable profit distribution policies in the future [1] Group 2 - The company is exploring diversified dividend methods based on situational assessments [1]

Core Insights - Huabang Health, established in 1992, is a leading enterprise in the field of clinical skin medications and skin health in China [1] - The company has developed a diversified business model focusing on the health industry, with independent operations in agricultural chemicals, new materials, and tourism [1] - Huabang Health's business scope includes five major areas: pharmaceuticals, medical services, agricultural chemicals, new materials, and tourism [1] Business Structure - The company controls three listed subsidiaries: Yingtai Biotechnology (920819.BJ), Kaisheng New Materials (301069.SZ), and Lijiang Co. (002033.SZ) [1] - It also holds a controlling stake in a New Third Board enterprise, Qinling Tourism (870256.NQ), and has a stake in another New Third Board company, Purikin (874090.NQ) [1] Future Strategy - The company plans to adhere to its development strategy in pharmaceuticals and medical health, continuously improving its full industry chain model that integrates raw materials, formulations, functional skincare products, comprehensive skin health management, and medical services [1] - Huabang Health aims to maintain the independent and stable operation of its three listed companies while leveraging its role as a controlling shareholder in governance [1]

（编辑 王雪儿） 证券日报网讯 华邦健康10月21日发布公告，在公司回答调研者提问时表示，公司目前构建了涵盖基本 医学、康复医学、健康及长寿医学的"医疗加健康"分层次业务生态，为客户提供全过程、全周期的一体 化医疗健康服务，帮助客户诊治病痛、改善健康、抗衰延寿。以出资建设的重庆松山医院为代表的基础 医疗聚焦疾病治疗，为患者提供基础诊疗和急症处理；以北京华生康复医院及德国莱茵河谷医院为代表 的医疗主体深耕康复医学，为患者提供专业化、系统化康复医疗服务；以重庆会员医院、巴拉塞尔系列 为代表的主体，为客户提供健康管理及抗衰延寿业务，并逐步向健康产品延伸。 ...